This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Acorda Therapeutics, Inc.

Drug Names(s): tizanidine hydrochloride (HCL)

Description: ZANAFLEX (tizanidine hydrochloride) isa centrally acting a2-adrenergic agonist. It presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. Zanaflex is supplied as 2 and 4 mg tablets and 2, 4, and 6 mg capsules for oral administration.

Zanaflex tablets are composed of the active ingredient, tizanidine hydrochloride (2.288 mg equivalent to 2 mg tizanidine base and 4.576 mg equivalent to 4 mg tizanidine base), and the inactive ingredients, silicon dioxide colloidal, stearic acid, microcrystalline cellulose and anhydrous lactose.

Zanaflex capsules are composed of the active ingredient, tizanidine hydrochloride (2.29 mg equivalent to 2 mg tizanidine base, 4.58 mgequivalent to 4 mg tizanidine base, and 6.87 mg equivalent to 6 mg tizanidine base), and the inactive ingredients, hydroxypropyl methyl cellulose, silicon dioxide, sugar spheres, titanium dioxide, gelatin, and colorants.

Deal Structure: Zanaflex tablets and capsules were both originally developed by Elan.

In July 2004, Acorda Therapeutics announced that it acquired rights to Zanaflex (tizanidine) from Elan Pharmaceuticals. Under the terms of the agreement, Acorda has acquired all sales, marketing and distribution rights in the United States to the Zanaflex tablet, which is currently on the market, as well as FDA-approved capsule formulation. Elan will supply Acorda with the capsule, for which Elan has retained manufacturing rights. Financial terms were not disclosed.

Elan and Alkermes
In May 2011, Alkermes and Elan announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies (EDT), the drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million. Alkermes and EDT will be combined under a new holding company incorporated in Ireland. This newly created company will be named...See full deal structure in Biomedtracker

Partners: Alkermes plc

Zanaflex News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug